Endre Grvik1, Kathinka Kurz Dhli2,
Atle Bjrnerud3, Kjell-Inge Gjesdal4
1University of Oslo, Oslo, Norway; 2Stavanger
University Hospital, Stavanger, Norway; 3Rikshospitalet University
Hospital, Oslo, Norway; 4Sunnmre MR-klinikk, Aalesund, Norway
This
work presents the transverse relaxation rate, R2*, as a quantitative
biomarker for distinguishing between malignant and benign breast lesions. R2*
was estimated on a pixel-by-pixel basis by assuming a mono-exponential
dependence of a double-echo intensity scheme, yielding from a high temporal resolution
sequence. The study suggested that the peak change in the transverse
relaxation rate is a sensitive biomarker for tumor malignancy in DSC
MR-mammography.
Keywords